Pinnacle Food Reports Laboratory-Scale Astaxanthin Extraction in Microalgae Programme
Pinnacle Food Group Limited says its Vancouver research team has extracted astaxanthin at laboratory scale after progressing through cultivation and stress-induction stages.
Pinnacle Food Group Limited (NASDAQ:PFAI) said its Canadian subsidiary, Pinnacle Food Inc., has completed astaxanthin extraction at laboratory scale as part of its Haematococcus pluvialis research programme. The work was conducted in-house at the company’s Vancouver laboratory and represents an early-stage research milestone.
The programme has moved through several stages, beginning with algal strain screening and followed by three-stage culture expansion. The company then carried out stress induction and astaxanthin accumulation before extracting the compound from the cultivated biomass.
Cultivation used a 500-liter photobioreactor. The subsequent extraction was performed at laboratory scale using a process developed in-house by Pinnacle Food.
Astaxanthin is a naturally occurring carotenoid, while Haematococcus pluvialis is a microalga widely studied as a source of the compound. Pinnacle Food said its current results remain limited to laboratory scale and that additional work is needed before commercial viability can be assessed.
The company said there is no assurance that the research will lead to a commercially viable process or product. Laboratory results may not be replicated or improved in later experiments or at larger scales, and the programme still faces uncertainties involving yields, purity, production costs and product quality.
Pinnacle Food intends to continue work on process optimisation and assess whether the programme can be scaled up. Chief Executive Officer Jiulong You described the completed workflow as an early-stage milestone and said the company would continue evaluating those areas within its microalgae biomanufacturing research.
The company also identified technical challenges related to cultivation, extraction, process development and scale-up. Other risks include intellectual property ownership, protection and freedom-to-operate; obtaining and maintaining required regulatory approvals; funding availability; competition; changes in market demand and pricing; and broader economic and industry conditions.
Pinnacle Food Group is a technology-driven company operating at the intersection of smart farming and bioengineering. The company says its activities include controlled-environment agricultural technologies, precision fermentation, synthetic biology and related engineering capabilities. Its shares trade on NASDAQ under the ticker PFAI.
Pinnacle Food’s Canadian subsidiary completed astaxanthin extraction at laboratory scale.
The programme uses Haematococcus pluvialis cultivated in a 500-liter photobioreactor.
The workflow has advanced through strain screening, culture expansion, stress induction, accumulation and extraction.
The results remain at laboratory scale, with further work required before commercial viability can be assessed.
The company plans further process optimisation and evaluation of scale-up feasibility, while identifying technical, regulatory, funding and market risks.
Pinnacle Food Group Limited announced that its Canadian subsidiary, Pinnacle Food Inc., achieved astaxanthin extraction at laboratory scale through in-house research at its Vancouver laboratory. The Company described this as an early-stage milestone in its research and development process.
Pinnacle Food Group Limited announced the development on November 17, 2026.
Pinnacle Food Group Limited said the workflow has progressed through algal strain screening, three-stage culture expansion, stress induction, astaxanthin accumulation and extraction of astaxanthin from cultivated biomass.
Pinnacle Food Group Limited said cultivation was carried out using a 500-liter photobioreactor, followed by laboratory-scale astaxanthin extraction using an in-house extraction process.
Pinnacle Food Group Limited said the results to date are at laboratory scale and that further work is required before any assessment of commercial viability can be made.
Pinnacle Food Group Limited intends to continue research towards process optimisation and evaluation of scale-up feasibility. Chief Executive Officer Jiulong You said the Company will continue evaluating process optimisation and scale-up feasibility as part of its microalgae biomanufacturing research.
Pinnacle Food Group Limited said there can be no assurance that its research will result in a commercially viable process or product. The Company also said further work is required before commercial viability can be assessed.
Pinnacle Food Group Limited identifies risks including the early stage of its microalgae research; the possibility that laboratory-scale results may not be replicated or improved upon in further experiments or at larger scales; and uncertainty over commercially viable yields, purity, production costs and product quality. It also cites technical challenges in cultivation, extraction, process development and scale-up; uncertainties over intellectual property ownership, protection and freedom-to-operate; required regulatory approvals; funding availability; competition; changes in market demand and pricing; and broader economic and industry conditions.
Astaxanthin is a naturally occurring carotenoid, while Haematococcus pluvialis is a microalga widely studied as a natural source of astaxanthin. Pinnacle Food Group Limited is researching the cultivation and extraction of astaxanthin from this microalga.
Pinnacle Food Group Limited describes itself as a technology-driven company operating at the intersection of smart farming and bioengineering. Through its "Dual-Engine" strategy, the Company seeks to combine controlled-environment agricultural technologies with precision fermentation, synthetic biology and related engineering capabilities to support the development and commercialisation of high-value biological products.
Pinnacle Food Group Limited is identified in the announcement as listed on NASDAQ under the ticker symbol PFAI.
Chief Executive Officer Jiulong You said the team had completed the laboratory workflow from strain screening through astaxanthin extraction. He described the development as an early-stage research milestone and said the Company would remain disciplined while evaluating process optimisation and scale-up feasibility.